Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levonorgestrel · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Levonorgestrel | DRUG | - |
| Ethinyl Estradiol | DRUG | - |
Inclusion Criteria: * Healthy women of legal age of consent who are willing to use a combination OC. * Subjects must be under the age of 36 at the time of enrollment (visit 3). * Subjects must have had regular (24 to 32 day) menstrual cycles for the 3-month period preceding entry into the pretreatm...
Levonorgestrel is a small molecule drug being developed by Pfizer, Inc. for use as an oral contraceptive and for contraception. It is also studied for menstruation disturbances, premenstrual syndrome, ovulation, and in healthy volunteers. It is currently in clinical development and is not approved.
Levonorgestrel is developed by Pfizer, Inc., which trades under the ticker symbol PFE. The drug is being studied in clinical trials for contraception and premenstrual syndrome, among other indications.
Levonorgestrel is in Phase 2 of clinical development. It has completed two Phase 3 trials and one Phase 1 trial, with a total of two completed trials and no active trials. It is investigational and not yet approved.
Levonorgestrel has been studied in clinical trials including NCT00128934, NCT00161681, NCT00195559, and NCT00319163. These trials evaluated the drug for premenstrual dysphoric disorder, premenstrual syndrome, and healthy volunteers, with enrollment ranging from 26 to 744 participants.
Levonorgestrel is often studied in combination with ethinyl estradiol, referred to as LNG/EE. Clinical trials such as NCT00128934 and NCT00161681 evaluate this combination for conditions like premenstrual dysphoric disorder and premenstrual syndrome.